GlassScriptPhysician profile
William Claytor
NPI 1023424587
$10,567.66
in general payments reported to CMS, 2019-2025
49 companies · $2,024 in 2025
The $2,024 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,499 · 2022: $2,398 · 2023: $2,232 · 2024: $2,416 · 2025: $2,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,671.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,241.45 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,156.65 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,154.72 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,075.18 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $932.38 | 2021-2025 | |
| Amgen INC. | $630.34 | 2021-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $601.27 | 2021-2025 | Jardiance, Synjardy, Ofev |
| Glaxosmithkline, LLC. | $464.87 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $360.64 | 2022-2025 | |
| Abbott Laboratories | $313.32 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Phathom Pharmaceuticals, INC. | $310.67 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $215.69 | 2021-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Biohaven Pharmaceutical Holding Company LTD. | $185.46 | 2022 | |
| Janssen Pharmaceuticals, INC | $175.08 | 2022-2025 | Spravato, Xarelto |
| Idorsia Pharmaceuticals US INC | $153.92 | 2022-2024 | Quviviq |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Claytor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.